VolitionRX (NYSEAMERICAN:VNRX) Issues Quarterly Earnings Results, Misses Expectations By $0.28 EPS

VolitionRX (NYSEAMERICAN:VNRX) issued its quarterly earnings data on Thursday. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28), FiscalAI reports. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million.

VolitionRX Stock Down 14.8%

Shares of NYSEAMERICAN:VNRX traded down $0.09 during midday trading on Friday, reaching $0.54. The company’s stock had a trading volume of 952,532 shares, compared to its average volume of 939,791. The firm has a 50 day moving average of $1.13 and a 200-day moving average of $2.74. The firm has a market capitalization of $4.64 million, a P/E ratio of -0.14 and a beta of 1.16. VolitionRX has a 12-month low of $0.53 and a 12-month high of $15.10.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of VNRX. Armistice Capital LLC grew its holdings in VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the period. Geode Capital Management LLC increased its stake in shares of VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 85,816 shares in the last quarter. Citadel Advisors LLC lifted its holdings in shares of VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in shares of VolitionRX during the second quarter valued at approximately $52,000. Finally, Squarepoint Ops LLC bought a new stake in shares of VolitionRX in the 4th quarter worth approximately $34,000. 8.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on VNRX shares. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Benchmark restated a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. Maxim Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of VolitionRX in a research report on Thursday, June 18th. Finally, Citigroup cut VolitionRX to a “hold” rating in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.00.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.